Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
NCT ID: NCT06221800
Last Updated: 2026-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
82 participants
OBSERVATIONAL
2024-01-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gut Microbiota and Cancer Immunotherapy Response
NCT04682327
Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC
NCT06613308
Study of the Correlation of Tumor Tissue Microbiome to the Pathogenesis of Lung Cancer
NCT04260295
Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer
NCT04063501
Exploratory Study of the Microbiome of Upper Gastrointestinal in the Pathogenesis of Multiple Primary Lung Cancer
NCT06973499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment with PD1/L1 monotherapy
Microbiome
Stool and saliva samples will be collected
Treatment with PD1/L1 + chemotherapy
Microbiome
Stool and saliva samples will be collected
Treatment with Tyrosine Kinase Inhibitor
Microbiome
Stool and saliva samples will be collected
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Microbiome
Stool and saliva samples will be collected
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. The patient himself/herself must be 18 years of age on day of signing informed consent.
* 3\. The subject has signed the informed consent form.
* 4\. The patient must be eligible to receive FDA approved and non-approved PD1 inhibitors (i.e. pembrolizumab, nivolumab) or PDL1 inhibitor (i.e. atezolizumab, durvalumab) either single agent or as combination therapy with chemotherapy, or be eligible to receive FDA approved and non-approved tyrosine kinase inhibitors.
* 5\. The subject will be registered upon submission of the samples. When submitted on separate dates, the submission occurring later will be considered the date of registration
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Irvine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Misako Nagasaka
Associate Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Misako Nagasaka, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Chao Family Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chao Family Comprehensive Cancer Center University of California, Irvine
Orange, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Chao Family Comprehensive Cancer Center University of California, Irvine
Role: CONTACT
University of California Irvine Medical
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCI 22-86
Identifier Type: OTHER
Identifier Source: secondary_id
3887
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.